New pill aims to ease Parkinson's motor symptoms when added to standard therapy
Disease control
Not yet recruiting
This phase 2 trial tests whether ENERGI-F705 tablets, taken twice daily alongside standard Parkinson's medications, can improve motor function and safety in people aged 40–75 with idiopathic Parkinson's disease. Participants are randomly assigned to receive a high dose, low dose,…
Phase: PHASE2 • Sponsor: Energenesis Biomedical Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC